Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

New Drugs from Old Classes

Spring 2006

A number of new drugs from existing classes are being studied. Here's a brief rundown of drugs that have started trials in people:


Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs)

  • Amdoxovir (DAPD): Early results from an ongoing Phase II study (in people resistant to other NRTIs) showed only a modest anti-HIV effect after two weeks on the drug.

  • AVX 754: active in vitro against HIV resistant to other NRTIs. Currently in early Phase II trials.

    Advertisement

  • Elvucitabine (ACH 126,443, L- Fd4C): active in vitro against HIV that is resistant to Epivir. Currently in Phase I trials. Also active against hepatitis B virus. It may be used once a day or perhaps even once a week.

  • Racivir (PSI 5004): similar to Emtriva (FTC); active against HIV and hepatitis B virus that is resistant to Epivir (3TC). Currently in Phase II trials.


Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

  • Etravirine (TMC 125): Recent study showed effectiveness in people resistant to Sustiva and Viramune; may be very strong in people who have never taken an NNRTI. Currently in Phase II trials. Taken twice a day.

  • TMC278 (DAPY): shows in vitro activity against NNRTI-resistant virus; in early development.


Protease Inhibitors (PIs)

  • Brecanavir (GW 640385): active in vitro against resistant virus. In Phase II trials. Taken with Norvir.

  • Darunavir (TMC 114): Phase II trial showed drug to be effective in people with multi-drug resistance -- may receive FDA approval as early as this summer. Taken twice daily with Norvir (ritonavir).




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More on Protease Inhibitors in Development

Tools
 

Advertisement